Details

Autor(en) / Beteiligte

• Toumia, Imene Ben
• Ponassi, Marco
• Barboro, Paola
• Iervasi, Erika
• Vargas, Gabriela Coronel
• Banelli, Barbara
• Fiordoro, Stefano
• Ghedira, Leila Chekir
• Kohnke, Franz Heinrich
• Izzotti, Alberto
• Rosano, Camillo

Titel

Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer

Ist Teil von

• Investigational new drugs, 2022-12, Vol.40 (6), p.1185-1193

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2022

Link zum Volltext

Quelle

SpringerLink Journals

Beschreibungen/Notizen

• Summary Macrocyclic compounds meso-(p-acetamidophenyl)-calix[4]pyrrole and meso-(m-acetamidophenyl)-calix[4]pyrrole have previously been reported to exhibit cytotoxic properties towards lung cancer cells. Here, we report pre-clinical in vitro and in vivo studies showing that these calixpyrrole derivatives can inhibit cell growth in both PC3 and DU145 prostatic cancer cell lines. We explored the impact of these compounds on programmed cell death, as well as their ability to inhibit cellular invasion. In this study we have demonstrated the safety of these macrocyclic compounds by cytotoxicity tests on ex-vivo human peripheral blood mononuclear cells (PBMCs), and by in vivo subcutaneous administration. Preliminary in vivo tests demonstrated no hepato-, no nephro- and no genotoxicity in Balb/c mice compared to controls treated with cisplatin. These findings suggest these calixpyrroles might be novel therapeutic tools for the treatment of prostate cancer and of particular interest for the treatment of androgen-independent castration-resistant prostate cancer.